The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T and androgen deprivation therapy (ADT) on immune markers in prostate cancer patients with a rising prostate specific antigen (PSA) after primary therapy.
E. S. Antonarakis
No relevant relationships to disclose
A. S. Kibel
Consultant or Advisory Role - Centocor Ortho Biotech; Dendreon; Sanofi
Honoraria - Centocor Ortho Biotech; Dendreon; Sanofi
D. W. Lin
Honoraria - Dendreon
R. C. Tyler
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
M. Tabesh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
C. G. Drake
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon
Honoraria - Institute for Medical Education Research
Other Remuneration - Bristol-Myers Squibb